These encouraging results led to a Phase I/IIa clinical trial (ClinicalTrials.gov ID-NCT02943850) aiming to assess the safety of transplantation of GDNF-producing human astrocyte-precursors into the spinal-cord lumbar segment of ALS patients. The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.